Disease · MONDO_0019499
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Turner Syndrome (TS) vs Growth Hormone Deficiency (GHD): serious adverse events | 0 of 149 | 1 of 169 | 318 | NCT00256126 | Trial comparisons |
| Treated-As-Randomized Control vs Treated-As-Randomized Humatrope: serious adverse events | 10 of 54 | 22 of 74 | 128 | NCT00191113 | Trial comparisons |
| As-Treated No Growth Hormone vs As-Treated Growth Hormone: Number of Participants With Abnormal Impedance Tympanometry, Audiologist Assessment | 2 of 19 | 18 of 53 | 72 | NCT00191113 | Trial comparisons |
| As-Treated No Growth Hormone vs As-Treated Growth Hormone: Number of Participants With an Abnormal Pure Tone Audiometry, Audiologist Assessment | 10 of 19 | 29 of 53 | 72 | NCT00191113 | Trial comparisons |
| As-Treated No Growth Hormone vs As-Treated Growth Hormone: Number of Participants With Abnormal Speech Audiometry, Audiologist Assessment | 3 of 19 | 12 of 53 | 72 | NCT00191113 | Trial comparisons |
| Early Treated vs Early Untreated: serious adverse events | 6 of 36 | 5 of 33 | 69 | NCT00266656 | Trial comparisons |
| As-Treated No Growth Hormone vs As-Treated Growth Humatrope: Number of Participants With Any Abnormal Fasting Insulin Value | 1 of 21 | 2 of 40 | 61 | NCT00191113 | Trial comparisons |
| As-Treated No Growth Hormone vs As-Treated Growth Hormone: Number of Participants With Any Abnormal Glycosylated Hemoglobin (HbA1c) Value | 0 of 21 | 0 of 40 | 61 | NCT00191113 | Trial comparisons |
| As-Treated No Growth Hormone vs As-Treated Growth Humatrope: Number of Participants With Any Abnormal Fasting Glucose Value | 0 of 21 | 3 of 39 | 60 | NCT00191113 | Trial comparisons |
| As-Treated No Growth Hormone vs As-Treated Growth Hormone: Number of Participants With Any Abnormal Fasting Glucose/Insulin Ratio Value | 1 of 21 | 3 of 38 | 59 | NCT00191113 | Trial comparisons |
| Growth Hormone vs Control: serious adverse events | 0 of 11 | 0 of 6 | 17 | NCT01367834 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019499/comparisons